Business Monitor International


Sweden Pharmaceuticals & Healthcare Report

Published 07 November 2014

  • 116 pages
  • Instant access to your report online and PDF format through your account library
  • Includes 3 free updated quarterly reports
 
$1,295.00
Sweden Pharmaceuticals & Healthcare Report

BMI View :   Declining government reimbursement for prescription medicines does not bode well for innovative drugmakers selling their products in Sweden , particularly as the government is the primary purchaser of pharmaceuticals. Furthermore, over the long   term, pushing costs onto a population with fewer young people to financially support the elderly will ultimately work to reduce the consumption of higher-value innovative pharmaceuticals.

Headline Expenditure Projections

  • Pharmaceuticals: SEK36.28bn (USD5.70bn) in 2013 to SEK36.41bn (USD5.36bn) in 2014; +0.38% in local currency terms and -5.9% in US dollar terms.

  • Healthcare: SEK351.16bn (USD55.18bn) in 2013 to SEK356.95bn (USD52.56bn) in 2014; +1.6% in local currency terms and -4.7% in US dollar terms.

Risk/Reward Index : We continue to view Sweden as a moderately attractive regional market. On the positive side, factors such as the country's high per capita incomes and strong regulatory foundations will continue to promote per capita spending on pharmaceuticals and healthcare in general. However, the downward pressure on pharmaceutical prices will continue to be acutely felt in this small market of fewer than 10mn people.

Key Trends And Developments

Sweden has the best healthcare system to deal with diabetes of all the EU member states, including Norway and Switzerland, as it has a better national registry, according to the 2014 Euro Diabetes Index launched in Vienna. Sweden was followed by the Netherlands, Denmark and the UK, while Bulgaria, Lithuania and Estonia scored lowest. The analysis, which came from the Health Consumer Powerhouse (HCP), was based on 28 defined indicators and areas, including prevention, case finding, range and reach of services, access to treatment and care, procedures and outcomes. Sweden only needs to improve its prevention under 'Exercise in compulsory school', according to the HCP.

About 850,000 false prescriptions are corrected by pharmacies every year in Sweden,...

Table of Contents

BMI Industry View
7
SWOT
9
Political
11
Economic
12
Business Environment
13
Industry Forecast
14
Pharmaceutical Market Forecast
14
Table: Pharmaceutical Sales, Historical Data And Forecasts (Sweden 2010-2018)
15
Healthcare Market Forecast
16
Table: Healthcare Expenditure Trends, Historical Data And Forecasts (Sweden 2010-2018)
17
Table: Government Healthcare Expenditure Trends, Historical Data And Forecasts (Sweden 2010-2018)
17
Table: Private Healthcare Expenditure Trends, Historical Data And Forecasts (Sweden 2010-2018)
18
Prescription Drug Market Forecast
19
Table: Prescription Drug Market Indicators, Historical Data And Forecasts (Sweden 2010-2018)
20
Patented Drug Market Forecast
21
Table: Patented Drug Market Indicators, Historical Data And Forecasts (Sweden 2010-2018)
22
Sweden Generic Drug Market Forecast
23
Table: Generics Drug Market Indicators, Historical Data And Forecasts (Sweden 2010-2018)
24
OTC Medicine Market Forecast
25
Table: OTC Sales by Therapeutic Group At Retail Prices, 2009-2010 (SEKmn)
26
Table: Over-The-Counter (OTC) Medicine Market Indicators, Historical Data And Forecasts (Sweden 2010-2018)
26
Pharmaceutical Trade Forecast
27
Table: Parallel Imported Pharmaceutical Market at Wholesale Prices, 1997-2010
28
Table: Pharmaceutical Trade Data And Forecast (Sweden 2012-2018)
29
Table: Pharmaceutical Trade Data And Forecasts local currency (Sweden 2012-2018)
29
Other Healthcare Data
30
Key Risks To BMI's Forecast Scenario
31
Macroeconomic Forecasts
32
Economic Analysis
32
GDP By Expenditure
34
Risks To Outlook
38
Table: Sweden - GDP By Expenditure
38
Industry Risk Reward Ratings
40
Western Europe Risk/Reward Ratings
40
Sweden Risk Reward Ratings
45
Rewards
45
Risks
46
Market Overview
47
Industry Trends And Developments
48
Epidemiology
48
Non-Communicable Disease
49
Communicable Disease
50
Healthcare System
50
Healthcare Financing
51
Research And Development
53
Table: Drug Development Member Companies of SwedenBIO, 2011
53
Clinical Trials Sector
54
Regulatory Development
58
Regulatory Regime
58
Intellectual Property Regime
59
Pricing Regime
60
Table: Price Decline For Off-Patent Drugs
61
Recent Pricing Developments
61
Reimbursement Regime
62
Competitive Landscape
64
Pharmaceutical Industry
64
Pharmaceuticals Manufacturing Sector
65
Table: Top Sweden-Based Pharmaceutical Companies By Market Capitalisation
65
Table: Leading Pharmaceutical Companies By Sales At Wholesale Prices, 2007-2010 (SEKmn)
66
Table: Pharmaceutical Sales By Leading Pharmaceutical Group At Wholesale Prices, 2007-2010 (SEKmn)
67
Pharmaceuticals Industry Developments
68
Pharmaceuticals Wholesaling
69
Pharmaceutical Retailing
72
Table: Drug Retail Establishments by Type, 2006-2010
73
Company Profile
76
Meda
76
Swedish Orphan Biovitrum (SOBI)
81
Medivir
87
GlaxoSmithKline
91
Pfizer
94
Novartis
97
Sanofi
100
Merck & Co
102
AstraZeneca
104
Demographic Forecast
108
Table: Sweden's Population By Age Group, 1990-2020 ('000)
109
Table: Sweden's Population By Age Group, 1990-2020 (% of total)
110
Table: Sweden's Key Population Ratios, 1990-2020
111
Table: Sweden's Rural And Urban Population, 1990-2020
111
Glossary
112
Methodology
114
Pharmaceutical Expenditure Forecast Model
114
Healthcare Expenditure Forecast Model
114
Notes On Methodology
115

The Sweden Pharmaceuticals & Healthcare Report features Business Monitor International (BMI)'s forecasts for drugs and healthcare expenditure and imports and exports, focusing on the growth outlook for the prescription, OTC, patented drugs and generics market segments.

BMI's Sweden Pharmaceuticals & Healthcare Report provides industry professionals, strategists, company executives, investors, analysts and sales/marketing heads with independent forecasts and competitive intelligence on the Swedish pharmaceutical and healthcare industry.

Key Benefits

  • Benchmark BMI's independent pharmaceutical and healthcare industry forecasts for Sweden to test other views - a key input for successful budgeting and strategic business planning in the Swedish pharmaceutical and healthcare market.
  • Target business opportunities and risks in the Swedish pharmaceutical and healthcare sector through our reviews of latest industry trends, regulatory changes and major deals, projects and investments in Sweden.
  • Assess the activities, strategy and market position of your competitors, partners and clients via our Company Profiles (inc. SWOTs, KPIs and latest activity) and Competitive Landscape Tables.

Coverage

BMI Industry View & Industry SWOT

An at-a-glance perspective on latest regulatory developments, key forecast indicators and major corporate developments, covering the prescription, OTC and generics markets. The SWOT outlines strategic factors which affect BMI's forecast analysis, and taken together with BMI's political, economic and business environment SWOTS, it gives a complete overview of market climate.

Market Summary

Snapshot of key market characteristics, including total size of pharmaceuticals and healthcare segments, growth drivers, leading therapeutic areas and the competitive landscape.

Regulatory Regime

Details of the industry regulatory framework and key legislation covering the licensing of new products/services, pricing and reimbursements, intellectual property, taxation and advertising, as well as an analysis of the overall regulatory burden.

Industry Developments

Focus on government healthcare reforms, epidemiological trends, company M&As, product launches, market entries, FDI activity, R&D, biotechnology, clinical trials and supply chain issues.

BMI Industry Forecasts

Forecasts to end-2018 for all key industry indicators (see list below) supported by explicit assumptions, plus analysis of key downside risks to the main forecast, including:

Healthcare: Total healthcare expenditure (US$bn), healthcare expenditure (% of GDP), healthcare expenditure per capita (US$), hospital beds (per `000 population), doctors (per `000 population), birth and mortality rate (per `000 population)

Pharmaceutical market: Drug expenditure (US$bn), drug expenditure (% of GDP), drug expenditure per capita (US$)

Patented drug market: Prescription drug sales (US$bn), prescription sales (% of total sales), sales broken down by 14 therapeutic areas (cardiovascular, anti-infectives etc.)

Generic drug market: Generic product sales (US$bn), generic sales (% of total sales)

OTC drug market: OTC sales (US$bn), OTC sales (% of total sales), sales broken down by product types (analgesics, skin treatments, vitamins and minerals etc.)

Medical Devices: Medical device sales (US$bn), medical device sales (% of total healthcare market)

Macroeconomic Forecasts: Nominal and real GDP, % real GDP growth, % private consumption growth, % industrial output growth, % consumer price index, % GDP price deflator, exports, imports, trade balance, current account balance, foreign direct investment, exchange rate against US$, government expenditure, external debt.

Competitive Landscape

The competitive landscape section provides comparative company analyses and rankings by US$ sales and % share of total sales - for the total pharmaceutical sector, as well as the OTC, generics, and distribution sub-sectors.

Company Profiles

Examines the competitive positioning and short- to medium-term business strategies of key industry players. Strategy is examined within the context of BMI's industry forecasts, our macroeconomic views and our understanding of the wider competitive landscape to generate Company SWOT analyses. The latest financial and operating statistics and key company developments are also incorporated within the company profiles, enabling a full evaluation of recent company performance and future growth prospects.

secure
Benefit from discounts when you add multiple products to your basket
2 Products SAVE 10%
3 Products SAVE 15%
4 Products SAVE 20%
5 Products SAVE 25%
6 Products SAVE 30%
7 - 20 Products SAVE 35%
21 Products or more SAVE 40%

Testimonials

'An essential, multi-faceted research tool. BMI’s thorough understanding of the major market players enables an informed – and informative – review of the sector’s actual performance, together with useful insights into current industry issues, which are topped-off with detailed and invaluable forecasts of industry and macroeconomic trends.’

Senior Research Analyst, ABC International Bank plc